Clinical trials: Age Related Macular Degeneration
Age-related Macular Degeneration
Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)
Age-related macular degeneration is a chronic degenerative retinal disease, which can lead to a progressive loss of visual acuity without affecting peripheral vision.
- Trial name
- FATTY (NCT04278300)
- Testing
- blood sampling, faecal sampling (optional)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Neovascular Age-related Macular Degeneration
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
In people with neovascular age-related macular degeneration (nAMD), the body makes too much of a protein called vascular endothelial growth factor (VEGF).
- Trial name
- BELUGA (NCT04641234)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Bayer
Age-Related Macular Degeneration
Alpha Lipoic Acid in Geographic Atrophy
Because of its iron-chelating and antioxidant properties, alpha lipoic acid may be a treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
- Trial name
- ALA (NCT02613572)
- Testing
- alpha lipoic acid
- Where
- 5 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Age-Related Macular Degeneration
Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly, characterized by multifactorial etiology.
- Trial name
- NCT06391411
- Testing
- a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg), anti-VEGF treatment
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Macular Degeneration, Retinal Vein Occlusion
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
The use of intravitreal injections of corticosteroid (triamcinolone acetonide) appears to be a promising treatment for a variety of ocular diseases associated with inflammation.
- Conditions
- Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT00101764
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Eye Institute (NEI)
Exudative Age-related Macular Degeneration
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Recently studies have shown that intravitreal injection of ranibizumab is effective for age related macular degeneration. However there are problems about injection regimen of maintenance phase.
- Trial name
- NCT02328209
- Testing
- ranibizumab
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Mie University
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Macular Degeneration
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.
- Trial name
- NCT00395707
- Testing
- Lucentis, Ranibizumab, Ranibizumab (Lucentis)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The National Retina Institute
Age Related Macular Degeneration (AMD)
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
The aim of this study is to test if PF582 (ranibizumab) is safe and similar to Lucentis (ranibizumab). Participants will have a screening visit to check for eligibility.
- Trial name
- NCT02121353
- Testing
- Lucentis, PF582
- Where
- 2 sites in New Zealand
- Volunteers
- 25 people
- Sponsor
- Pfenex, Inc
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Blindness, Cataract
Long Term Follow-Up of Diabetic Retinopathy
The efficacy of laser photocoagulation treatment for diabetic retinopathy has been demonstrated by several National Eye Institute (NEI) sponsored clinical trials.
- Conditions
- Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy
- Trial name
- NCT00001395
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Eye Institute (NEI)
Stargardt Disease, Stargardt Macular Degeneration
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1).
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Trial name
- ASTRA (NCT06942572)
- Testing
- SB-007
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Splice Bio
Chronic Diseases, Low Vision
Living Successfully With Chronic Eye Diseases
The need for low vision services (LVS) will increase exponentially over the coming years due to the anticipated and exponential growth in the ageing population in Singapore and a rise in chronic non-communicable eye diseases.
- Conditions
- Chronic Diseases, Low Vision, Diabetic Retinopathy, Glaucoma
- Trial name
- ADAPT-LAH (NCT01879501)
- Testing
- Low Vision Self-Management Program
- Where
- Singapore
- Volunteers
- 160 people
- Sponsor
- Singapore Eye Research Institute
Neovascular Age Related Macular Degeneration
NVAMD Satellite Study
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD).
- Trial name
- NCT02251366
- Testing
- Physician-guided diagnostic
- Where
- 5 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Macular Edema, Cystoid
Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling
Aim of the study is to assess the rate of postoperative intraretinal cystoid changes after pars plana vitrectomy with membrane peeling and peribulbar application of triamcinolone acetonide and to examine possible risk factors for…
- Trial name
- NCT04472039
- Testing
- optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Dry Eye Syndromes, Age-Related Macular Degeneration
Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50. Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks apart usually depending on…
- Trial name
- TREDIA (NCT06174181)
- Testing
- Preservative-free ophtalmic lubricant emulsion, Routine treatment
- Where
- 2 sites in France
- Volunteers
- 42 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
AMD - Age-Related Macular Degeneration
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular…
- Trial name
- NCT07418177
- Testing
- hiPSC-RPEs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Geographic Atrophy
Evolution and Risk Factors Associated With Geographic Atrophy Progression
Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly…
- Trial name
- GAIN (NCT01694095)
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut de la Macula y la Retina
Diabetic Retinopathy, Glaucoma
AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries.
- Conditions
- Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Choroidal Nevus
- Trial name
- NCT04132401
- Testing
- algorithm
- Where
- Spain
- Volunteers
- 902 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.